Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies

适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性

基本信息

  • 批准号:
    10229391
  • 负责人:
  • 金额:
    $ 26.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a zoonotic virus that can cause fatal disease in patients with underlying comorbidities. Further recognition of this respiratory syndrome and prevention strategies will require a small animal infection model as well as an additional understanding of the virus. This PPG describes a mouse model of MERS-CoV disease. In this model, the viruses causing disease are adapted variants, specialized for mouse lung infection. By contrast, non- adapted MERS-CoVs cause infection in the mouse but do not cause disease. The central hypothesis of this subproject (PPG2) is that mouse-adapted variants can efficiently enter host cells through pathways that are not available to the non-adapted viruses. To address this hypothesis, recombinant MERS-CoVs will be constructed and evaluated to determine whether mouse-adaptive mutations in the cell entry-mediating viral spike proteins correlate with efficient mouse lung infection. Surrogate MERS-CoV pseudo-viruses will be constructed and evaluated to address the focused hypothesis that mouse adapted variants mediate an “early” plasma-membrane cell entry that is unavailable to non-adapted viruses. The project will dissect mechanisms by which spike proteins mediate early cell entry through plasma membranes versus late cell entry through endosomes. The basis for selection of early versus late cell entry will be determined by identifying host cell factors promoting or restricting either pathway. This project will also identify appropriate antiviral strategies that operate by preventing early and late virus-cell entry. The rationale for all of these aims is that additional understanding of MERS-CoV cell entry pathways will identify correlates of robust infection and disease, and will also provide insights on the best ways to prevent infection and disease with innovative virus entry inhibitors.
项目概要 中东呼吸综合征冠状病毒(MERS-CoV)是一种人畜共患病毒 这可能会导致患有潜在合并症的患者患上致命疾病。更远 对这种呼吸综合征的认识和预防策略需要少量的努力 动物感染模型以及对病毒的进一步了解。这个PPG 描述了中东呼吸综合征冠状病毒疾病的小鼠模型。在这个模型中,病毒引起 该疾病是适应变种,专门针对小鼠肺部感染。相比之下,非 适应的中东呼吸综合征冠状病毒会引起小鼠感染,但不会引起疾病。这 该子项目(PPG2)的中心假设是,适应小鼠的变体可以 通过非适应者无法利用的途径有效进入宿主细胞 病毒。为了解决这一假设,将构建重组中东呼吸综合征冠状病毒并 评估以确定细胞进入介导中是否存在小鼠适应性突变 病毒刺突蛋白与有效的小鼠肺部感染相关。替代中东呼吸综合征冠状病毒 将构建和评估伪病毒,以解决以下重点假设: 小鼠适应变体介导“早期”质膜细胞进入,即 对于非适应性病毒不可用。该项目将剖析峰值的机制 蛋白质介导通过质膜的早期细胞进入与晚期细胞进入 通过内体。选择早期与晚期细胞进入的基础是 通过识别促进或限制任一途径的宿主细胞因子来确定。这 项目还将确定适当的抗病毒策略,通过预防早期 和晚期病毒进入细胞。所有这些目标的基本原理是额外的 了解 MERS-CoV 细胞进入途径将确定稳健的相关性 感染和疾病,还将提供有关预防感染的最佳方法的见解 和疾病与创新的病毒进入抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas Miller Gallagher其他文献

Thomas Miller Gallagher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas Miller Gallagher', 18)}}的其他基金

Impacts of Adaptive Coronavirus Evolution on Viral Membrane Fusion
冠状病毒适应性进化对病毒膜融合的影响
  • 批准号:
    10727448
  • 财政年份:
    2023
  • 资助金额:
    $ 26.63万
  • 项目类别:
Dissecting the peptide motifs controlling coronavirus infections
剖析控制冠状病毒感染的肽基序
  • 批准号:
    10648391
  • 财政年份:
    2023
  • 资助金额:
    $ 26.63万
  • 项目类别:
Entry and pathogenesis of two human coronaviruses
两种人类冠状病毒的进入和发病机制
  • 批准号:
    8055141
  • 财政年份:
    2011
  • 资助金额:
    $ 26.63万
  • 项目类别:
Entry and Pathogenesis of Coronaviruses
冠状病毒的进入和发病机制
  • 批准号:
    8321679
  • 财政年份:
    2011
  • 资助金额:
    $ 26.63万
  • 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
  • 批准号:
    7646778
  • 财政年份:
    2009
  • 资助金额:
    $ 26.63万
  • 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
  • 批准号:
    7846495
  • 财政年份:
    2009
  • 资助金额:
    $ 26.63万
  • 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
  • 批准号:
    7860419
  • 财政年份:
    2009
  • 资助金额:
    $ 26.63万
  • 项目类别:
Biological Effects of SARS-CoV Spike Polymorphisms
SARS-CoV 刺突多态性的生物学效应
  • 批准号:
    6825526
  • 财政年份:
    2004
  • 资助金额:
    $ 26.63万
  • 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
  • 批准号:
    9209899
  • 财政年份:
    2004
  • 资助金额:
    $ 26.63万
  • 项目类别:
MOLECULAR DISSECTION OF THE CORONAVIRUS SPIKE
冠状病毒刺突的分子解剖
  • 批准号:
    6320275
  • 财政年份:
    1993
  • 资助金额:
    $ 26.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了